

A2 4(Amended). A compound as claimed in claim 1, wherein said dendrimeric polymer backbone comprises from 3 to 200 amino acid residues extending radially from a central core display.

8(Amended). A compound as claimed in claim 1, wherein said polymer backbone has a molecular weight of from 300 to 20,000 daltons.

A3 9(Amended). A compound as claimed in claim 2, wherein said polymer backbone comprises a polymer of a single species or at least two different species of amino acids, or a block copolymer.

11(Amended). A compound as claimed in claim 1 comprising from 3 to 200 reporter moieties.

12(Amended). A compound as claimed in claim 1, wherein each reporter moiety is linked to said polymer backbone via a biodegradable linking group.

A5 15(Amended). A compound as claimed in claim 1, wherein at least one reporter moiety comprises a diagnostic or therapeutic agent.

A6 19(Amended). A compound as claimed in claim 16, wherein said chelating agent is selected from ethylenediamine tetraacetic acid (EDTA), diethylenediamine pentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A), 1-oxa-4,7,10-triazacyclononanetriacetic acid (NOTA) and 1,4,8,11-tetraazacyclotetradecanetetraacetic acid (TETA).

20(Amended). A compound as claimed in claim 16, wherein said chelating agent is selected from 4' - (3-amino-4-methoxy-phenyl)-6,6"-bis(N', N'-dicarboxymethyl-N-

AF methylhydrazino)-2,2''6', 2''-terpyridine (THT) and 4'-(d-amino-4-methoxy-phenyl)-6,6''-bis[N,N-di(carboxymethyl) aminomethyl]-2,2':6',2''-terpyridine (TMT).

---

22(Amended). A compound as claimed in claim 1 linked to a targeting agent capable of traveling to or binding specifically to targeted cells, tissues, organs or other locations in a mammalian body.

---

23(Amended). A compound as claimed in claim 7, wherein said targeting agent comprises *E. coli* heat stable enterotoxin Sta or an analogue thereof.

---

25(Amended). A dendrimeric polymer as claimed in claim 24, wherein said core moiety is as defined.

---

26(Amended). A process for preparing a compound as claimed in claim 1, said process comprising conjugating at least one reporter moiety to a radially asymmetric dendrimeric polymer backbone comprising a plurality of amino acid residues.

---

27(Amended). A process for preparing a compound as claimed in claim 1, said process comprising the step of deprotecting a partially or fully protected derivative thereof.

---

29(Amended). A pharmaceutical composition comprising a compound as claimed in claim 1, together with at least one pharmaceutical carrier or excipient.

---

30(Amended). Use of a compound as claimed in claim 1 in the manufacture of an image enhancing contrast medium or a therapeutic composition.

---

31(Amended). A method of generating an image of the human or non-human animal body, said method comprising the step of administering to said body a

---

compound as claimed in claim 1 and thereafter generating an image of at least a part of said body.

20057943-042001